Search Our Scientific Publications & Authors

Ann Transl Med 2022 Jul;10(14):809

Department of Respiratory and Critical Care Medicine, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.

Background: Numerous clinical studies have established the efficacy and safety of gefitinib for treating patients with epidermal growth factor receptor ()-mutant lung cancer. Gefitinib-induced urinary system-related adverse reactions are rare but may lead to discontinuation of gefitinib.

Case Description: In our report, we describe a patient with advanced lung adenocarcinoma harboring compound G719S and S768I who developed hemorrhagic cystitis and inflammatory contracted bladder during first-line gefitinib therapy. Read More

J Mol Diagn 2022 Aug 10. Epub 2022 Aug 10.

Janssen R&D, Spring House, PA, USA.

Amivantamab, an epidermal growth factor receptor (EGFR)-MET bispecific antibody, targets activating/resistance EGFR mutations and MET mutations/amplifications. In the ongoing CHRYSALIS study (NCT02609776), amivantamab demonstrated antitumor activity in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations (ex20ins) that progressed on or after platinum-based chemotherapy, a population for which amivantamab received US FDA approval. A bridging study was conducted to clinically validate two novel candidate companion diagnostics for detecting EGFR ex20ins in plasma and tumor tissue, Guardant360 CDx and Oncomine Dx Target Test (ODxT Test), respectively. Read More

J Clin Oncol 2022 Aug 12:JCO2102911. Epub 2022 Aug 12.

Department of Palliative Medicine, Tohoku University School of Medicine, Sendai, Japan.

JCO In a randomized, open-label, phase III NEJ009 study, gefitinib plus chemotherapy significantly improved progression-free survival (PFS) and overall survival (OS) compared with gefitinib-alone in patients with untreated non-small-cell lung cancer harboring mutations in epidermal growth factor receptor. Herein, we report the updated survival outcome and long-term tolerability. Patients were randomly assigned to gefitinib (gefitinib 250 mg orally, once daily) and gefitinib combined with carboplatin plus pemetrexed (GCP in a 3-week cycle for six cycles followed by concurrent gefitinib and pemetrexed maintenance) groups. Read More

Medicine (Baltimore) 2022 Aug;101(32):e29682

Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan.

Rationale: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used for the treatment of EGFR mutation positive advanced nonsmall cell lung cancer (NSCLC); however, acquired resistance is known to develop during these treatments. Among these mechanisms, histological transformation is seldom encountered. Although platinum based chemotherapy has been reported to be effective in the treatment of patients with small cell lung cancer transformation, there is a lack of information on the treatment of patients with squamous cell carcinoma (SQ) transformation. Read More

Transl Lung Cancer Res 2022 Jul;11(7):1497-1502

Department of Medical Oncology, Ramón y Cajal University Hospital, Madrid, Spain.

Paraneoplastic cerebellar degeneration (PCD) is one of the most prevalent neurological paraneoplastic syndromes, typically associated with small cell lung cancer (SCLC). PCD is thought to be caused by proteins expressed by tumor cells which trigger an antibody-mediated immune response. Despite PCD being commonly associated with anti-Yo, anti-Hu and anti-Tr/DNER antibodies, PCD is the most prevalent paraneoplastic syndrome in patients harboring anti-Zic4 antibodies. Read More